Opdivo granted accelerated approval for melanoma

Opdivo granted accelerated approval for melanoma
Opdivo granted accelerated approval for melanoma

The Food and Drug Administration has granted accelerated approval for Opdivo (nivolumab; Bristol-Myers Squibb) injection for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab (Yervoy) and, if BRAF V600 mutation positive, a BRAF inhibitor.

Opdivo is a human programmed death receptor-1 (PD-1) blocking antibody that works to prevent the inhibition of the immune system in attacking the melanoma tumors. Its efficacy was established in patients with unresectable or metastatic melanoma (n=120). Results showed that 32% of patients treated with Opdivo had shrinkage in their tumors. About one-third of the patients with tumor shrinkage achieved the objective response rate of six months.

RELATED: Opdivo Achieves Primary Endpoint in Melanoma Trial

Opdivo was granted breakthrough therapy designation, priority review, and orphan drug designation. Opdivo will be available as 40mg/4mL or 100mg/10mL strengths in single-use vials.

For more information call (800) 321-1335 or visit BMS.com.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs